Study of Insulin Pump Discontinuation in Adults With Diabetes (STOPPOMPE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04915066|
Recruitment Status : Recruiting
First Posted : June 7, 2021
Last Update Posted : June 7, 2021
|Condition or disease||Intervention/treatment|
|Diabetes Mellitus||Other: Medical data collection|
Insulin pump discontinuation has been mostly studied in children and young adults living with diabetes, and rarely with a time-to-event analysis. We aim to evaluate the rate of insulin pump discontinuation after 18 months from initiation and factors associated with it in adults with diabetes.
Knowing these factors would allow better support for patients in difficulty.
|Study Type :||Observational|
|Estimated Enrollment :||315 participants|
|Official Title:||Probability and Factors Associated With Early Discontinuation of Insulin Pump Therapy in Adults With Diabetes at the Center Hospitalier Sud Francilien|
|Estimated Study Start Date :||June 5, 2021|
|Estimated Primary Completion Date :||September 1, 2021|
|Estimated Study Completion Date :||October 1, 2021|
- Other: Medical data collection
Collection of medical data from patients'medical records
- Permanent discontinuation of insulin pump use. [ Time Frame: at 18 months ]Insulin pump discontinuation is considered permanent if > 6 consecutive months with patient back to insulin pen and no use of pump-related consumables during the 6 months.
- Age [ Time Frame: at day 0 ]Age of patient at the moment of insulin pump discontinuation.
- Sex [ Time Frame: at day 0 ]Sex of patient
- type of diabete [ Time Frame: at day 0 ]type 1 or 2
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04915066
|Contact: Alfred PENFORNIS, PHD||(33) 1 61 69 75 firstname.lastname@example.org|
|Contact: Caroline TOURTE GROSPIRON||(33) 1 61 69 31 email@example.com|
|Centre Hospitalier Sud Francilien||Recruiting|
|Corbeil-essonnes Cedex, France, 91106|
|Contact: Alfred PENFORNIS (33) 1 61 69 75 50 firstname.lastname@example.org|
|Principal Investigator: Coralie AMADOU, MD|